Development of a Guideline for Antipsychotic-induced Hyperprolactinemia in Korea Using the ADAPTE Process
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: To develop an evidence-based guideline for the diagnosis and treatment of antipsychotic-induced hyperprolactinemia by adapting existing high-quality clinical guidelines with a view to improve the clinical symptoms and long-term quality of life of patients by providing appropriate management. Methods: This guideline was developed according to the ADAPTE methodology. The adaptation process included determining key health questions, systematically searching and screening guidelines, evaluating the quality and contents of these guidelines, deriving recommendations for key questions, and performing a peer review. The selection criteria for the guideline search were (1) evidence-based guidelines, (2) published within the last 5 years, and (3) written in English or Korean. Results: After evaluating the quality and content, we finally selected three guidelines for adaptation. The final output of the development process was 25 recommendations for 10 key questions. We adopted the Agency for Health Research Quality methodology and presented the level of evidence from levels I to IV. In addition, we defined the recommendation grades from grade A (strongly recommended) to D (no recommendation) based on the level of evidence and clinical significance of the recommendation. Conclusion: The development and dissemination of the adapted guideline is expected to increase the certainty of medical decision making and improve the quality of medical care. Further studies on the effectiveness and applicability of the developed guideline are necessary.
Abstract
Objective: To develop an evidence-based guideline for the diagnosis and treatment of antipsychotic-induced hyperprolactinemia by adapting existing high-quality clinical guidelines with a view to improve the clinical symptoms and long-term quality of life of patients by providing appropriate management. Methods: This guideline was developed according to the ADAPTE methodology. The adaptation process included determining key health questions, systematically searching and screening guidelines, evaluating the quality and contents of these guidelines, deriving recommendations for key questions, and performing a peer review. The selection criteria for the guideline search were (1) evidence-based guidelines, (2) published within the last 5 years, and (3) written in English or Korean. Results: After evaluating the quality and content, we finally selected three guidelines for adaptation. The final output of the development process was 25 recommendations for 10 key questions. We adopted the Agency for Health Research Quality methodology and presented the level of evidence from levels I to IV. In addition, we defined the recommendation grades from grade A (strongly recommended) to D (no recommendation) based on the level of evidence and clinical significance of the recommendation. Conclusion: The development and dissemination of the adapted guideline is expected to increase the certainty of medical decision making and improve the quality of medical care. Further studies on the effectiveness and applicability of the developed guideline are necessary.
참고문헌 (36)
- Ajmal A, "Psychotropic-induced hyperprolactinemia : A clinical review", Psychosomatics, 55, pp.29~36 (2014)
- Halperin Rabinovich I, "Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia", Endocrinol Nutr, 60, pp.308~319 (2013)
- Kinon BJ, "Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone", Psychoneuroendocrinology, 28(Suppl 2), pp.55~68 (2003)
- Inder WJ, "Antipsychotic-induced hyperprolactinaemia", Aust N Z J Psychiatry, 45, pp.830~837 (2011)
- Jung DU, "The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia", J Clin Psychopharmacol, 25, pp.613~615 (2005)
- 이가희, "항정신병약물을 복용중인 정신분열병 환자에서 고프로락틴혈증과 무월경 유병률 및 성기능 장애와 관련성", 신경정신의학, 48(6), pp.422~428 (2009), 대한신경정신의학회
- Madhusoodanan S, "Hyperprolactinemia associated with psychotropics--a review", Hum Psychopharmacol, 25, pp.281~297 (2010)
- Freeman ME, "Prolactin : Structure, function, and regulation of secretion", Physiol Rev, 80, pp.1523~1631 (2000)
- Serri O, "Diagnosis and management of hyperprolactinemia", CMAJ, 169, pp.575~581 (2003)
- 대한내분비학회, "고프로락틴혈증(hyperprolactinemia)의 진료지침", Endocrinology and Metabolism, 25(3), pp.180~182 (2010), 대한내분비학회
- 윤제연, "‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료", 대한조현병학회지, 22(2), pp.21~33 (2019), 대한조현병학회[DOI]
- Melmed S, "Diagnosis and treatment of hyperprolactinemia : An Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 96, pp.273~288 (2011)
- Kearns AE, "Risperidoneassociated hyperprolactinemia", Endocr Pract, 6, pp.425~429 (2000)
- Byerly M, "Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders : Recent developments and current perspectives", J Clin Psychopharmacol, 27, pp.639~661 (2007)
- Montejo ÁL, "Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia", Rev Psiquiatr Salud Ment, 9, pp.158~173 (2016)
- Galletly C, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders", Aust N Z J Psychiatry, 50, pp.410~472 (2016)
- Kawaguchi R, "Guidelines for office gynecology in Japan : Japan Society of Obstetrics and Gynecology(JSOG)and Japan Association of Obstetricians and Gynecologists(JAOG)2017edition", J Obstet Gynaecol Res, 45, pp.766~786 (2019)
- Pringsheim T, "Physical health and drug safety in individuals with schizophrenia", Can J Psychiatry, 62, pp.673~683 (2017)
- Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
- Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia : Updated recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 34, pp.3~78 (2020)
- Grigg J, "Antipsychotic-induced hyperprolactinemia: Synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research", Psychopharmacology(Berl), 234, pp.3279~3297 (2017)
- Tewksbury A, "Management of antipsychotic-induced hyperprolactinemia", Ment Health Clin, 6, pp.185~190 (2016)
- The ADAPTE Collaboration, "The ADAPTE process: Resource toolkit for guideline adaptation. Version 2.0", ADAPTE Collaboration, ~ (2009)
- The AGREE Collaboration, "The Appraisal of Guidelines for Research & Evaluation(AGREE) instrument", The AGREE Research Trust, ~ (2001)
- Kim SY, "NECA’s handbook for clinical practice guideline development", National Evidence-based Healthcare Collaborating Agency, ~ (2015)
- Montejo ÁL, "Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics", Front Neuroendocrinol, 45, pp.25~34 (2017)
- Kinon BJ, "Bone loss associated with hyperprolactinemia in patients with schizophrenia", Clin Schizophr Relat Psychoses, 7, pp.115~123 (2013)
- Kishimoto T, "Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia", J Clin Psychiatry, 69, pp.385~391 (2008)
- Takahashi T, "The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia : Findings from a longitudinal observational cohort", Schizophr Res, 147, pp.383~386 (2013)
- dos Santos Nunes V, "Cabergoline versus bromocriptine in the treatment of hyperprolactinemia : A systematic review of randomized controlled trials and meta-analysis", Pituitary, 14, pp.259~265 (2011)
- Fachi MM, "Efficacy and safety in the treatment of hyperprolactinemia : A systematic review and network meta-analysis", J Clin Pharm Ther, 46, pp.1549~1556 (2021)
- Lee MS, "Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia : Eight-week randomized, single-blind, placebo-controlled, multicenter study", Psychiatry Clin Neurosci, 64, pp.19~27 (2010)
- Andersohn F, "Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists", Mov Disord, 24, pp.129~133 (2009)
- Chang SC, "Cabergoline-induced psychotic exacerbation in schizophrenic patients", Gen Hosp Psychiatry, 30, pp.378~380 (2008)
- Hashimoto K, "The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients : A preliminary study", Neuropsychiatr Dis Treat, 10, pp.1571~1576 (2014)
- Yuan HN, "A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia", J Clin Psychopharmacol, 28, pp.264~370 (2008)